1. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105–87.
2. HernЗndez-HernЗndez R, Sosa-Canache B, Velasco M et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002; 16 (Suppl. 1): S93–99.
3. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4 (3): 120–6.
4. Шальнова С.А. Проблемы лечения артериальной гипертонии. Кардиоваскул. терапия и профилактика. 2003; 3: 17–21.
5. Mochizuki S, Shimuzu M, Taniguchi I et al. for the JIKEI HEART Study Group. JIKEI HEART Study – А morbid-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease. Cardiovasc Drugs Ther 2004; 18: 305–9.
6. Mochizuki S, Dahlof B, Taniguchi I et al. for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
7. Grajek S, Cieslinski A, Mitkowski P et al. Results of long-term medical treatment of patients with arterial hypertension complicated by aortic dissection. J Hum Hypertens 1995; 9 (12): 987–92.
8. Coady MA, Rizzo JA, Goldstein LJ et al. Natural history, pathogenesis, and etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999; 17 (4): 615–35.
9. Onitsuka S, Akashi H, Tayama K et al. Long-term outcome and prognostic predictors of medically treated acute type B aortic dissections. Ann Thorac Surg 2004; 78 (4): 1268–73.
10. Beltran A, McVeigh G, Morgan D et al. Arterial compliance abnormalities in isolated systolic hypertension. Am J Hypertens 2001; 14: 1007-11.
11. Бойцов С.А. Изучение патогенеза гипертонической болезни продолжается. Тер. арх. 2006; 9: 5–12.
12. The CAFГ Investigators. Differential impact of blood-pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFГ) study. Circulation 2006; 113 (9): 1213–25.
13. Labat C, Lacolley P, Lajemi M et al. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension 2001; 38 (3): 439–43.
14. Nakamura T, Fujii S, Hoshino J et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28 (12): 937–43.
15. Malacco E, Vari N, Capuano V et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003; 25: 2765–80.
16. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847–57.
17. Calvo C, Hermida RC, Ayala DE et al. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22 (4): 837–46.
18. Kirn S, Iwao H. Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11–34.
19. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone receptor blockade. J Hypertens 2005; 23 (Suppl. 1): 1–17.
20. Wolf G. Molecular mechanisms of angiotensin II in the kidney; emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998; 13: 1131–42.
21. Xie QY, Wang YJ, Sun ZL, Yang TL. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31 (5): 629–34.
22. Manabe S, Okura T, Watanabe S et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc. Pharmacol 2005; 46 (6): 735–9.
23. Cottone S, Vadala A, Mangano MT et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens 2000; 13: 172–6.
24. Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens 2004; 13: 489–93.
25. Remuzzi G, Weening JJ. Albuminuria as early test for vascular disease. Lancet 2005; 365: 556–7.
26. Klingbeil AU, John S, Schneider MP et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16 (2): 123–8.
27. Inoue M, Fujii S, Taisei M et al. Dilation of the brachial artery in response to sublingual nitroglycerin can predict the antihypertensive effects of valsartan: a study using novel high-frequency high-frame-rate ultrasound imaging. J Cardiol 2006; 47 (1): 9–14.
28. Ikeda F, Azuma K, Ogihara T et al. Angiotensin II type 1 receptor blocker reduces monocyte adhesion to endothelial cells in spontaneously hypertensive rats. Endocr J 2007; 54 (4): 605–12.
29. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672–8.
30. Katayama S, Yagi S, Yamamoto H et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res 2007; 30 (6): 529–33.
31. Watanabe S, Okura T, Kurata M et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006; 28 (5): 451–61.
32. Fu CH, Yang CC, Kuo TB. Effects of different classes of antihypertensive drugs on cerebral hemodynamics in elderly hypertensive patients. Am J Hypertens 2005; 18 (12 Pt. 1): 1621–5.
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.

В.В.Фомин

Кафедра терапии и профболезней (зав. – акад. РАМН Н.А.Мухин) ММА им. И.М.Сеченова